SG11202013027RA - Amino acid compounds with unbranched linkers and methods of use - Google Patents
Amino acid compounds with unbranched linkers and methods of useInfo
- Publication number
- SG11202013027RA SG11202013027RA SG11202013027RA SG11202013027RA SG11202013027RA SG 11202013027R A SG11202013027R A SG 11202013027RA SG 11202013027R A SG11202013027R A SG 11202013027RA SG 11202013027R A SG11202013027R A SG 11202013027RA SG 11202013027R A SG11202013027R A SG 11202013027RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- amino acid
- acid compounds
- unbranched
- linkers
- Prior art date
Links
- -1 Amino acid compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Devices That Are Associated With Refrigeration Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690939P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/039624 WO2020006315A1 (fr) | 2018-06-27 | 2019-06-27 | Composés d'acides aminés avec des lieurs non ramifiés et procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202013027RA true SG11202013027RA (en) | 2021-01-28 |
Family
ID=68987528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013027RA SG11202013027RA (en) | 2018-06-27 | 2019-06-27 | Amino acid compounds with unbranched linkers and methods of use |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11396506B2 (fr) |
| EP (1) | EP3813818A4 (fr) |
| JP (2) | JP7425757B2 (fr) |
| KR (1) | KR20210043561A (fr) |
| CN (1) | CN112689507A (fr) |
| AU (1) | AU2019295769B2 (fr) |
| BR (1) | BR112020026278A2 (fr) |
| CA (1) | CA3104682A1 (fr) |
| CL (1) | CL2020003382A1 (fr) |
| CR (1) | CR20210041A (fr) |
| CU (1) | CU24693B1 (fr) |
| DO (1) | DOP2020000255A (fr) |
| EA (1) | EA202190134A1 (fr) |
| EC (1) | ECSP21005655A (fr) |
| IL (2) | IL279717B2 (fr) |
| JO (1) | JOP20200330A1 (fr) |
| MX (1) | MX2020014086A (fr) |
| PE (1) | PE20210137A1 (fr) |
| PH (1) | PH12020552260A1 (fr) |
| SG (1) | SG11202013027RA (fr) |
| WO (1) | WO2020006315A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (fr) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | Composés d'acides aminés n-acyle et méthodes d'utilisation |
| EP3558303A4 (fr) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | Composés acides aminés et leurs procédés d'utilisation |
| CA3045491A1 (fr) | 2016-12-29 | 2018-07-19 | Indalo Therapeutics, Inc. | Antagonistes de l'integrine |
| EP3589627A4 (fr) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| DK3761980T3 (da) | 2018-03-07 | 2024-01-29 | Pliant Therapeutics Inc | Aminosyreforbindelser og fremgangsmåder til anvendelse |
| SI3814348T1 (sl) | 2018-06-27 | 2023-10-30 | Bristol-Myers Squibb Company | Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic |
| CU24693B1 (es) | 2018-06-27 | 2024-02-07 | Pliant Therapeutics Inc | Compuestos de aminoácido con enlazadores no ramificados como inhibidores de la integrina |
| PE20211640A1 (es) | 2018-08-29 | 2021-08-24 | Morphic Therapeutic Inc | INHIBICION DE LA INTEGRINA xvß6 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| JP2022526818A (ja) | 2019-04-08 | 2022-05-26 | プライアント・セラピューティクス・インコーポレイテッド | アミノ酸化合物の剤形およびレジメン |
| CA3165000A1 (fr) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Traitement combine de maladies hepatiques a l'aide d'inhibiteurs de l'integrine |
| CA3164941A1 (fr) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Polytherapie de maladies hepatiques a l'aide d'inhibiteurs d'integrine |
| GB202209228D0 (en) | 2022-06-23 | 2022-08-10 | Univ Strathclyde | Modified amino acids and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010033248A (ko) * | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6329372B1 (en) * | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| JP2009539815A (ja) * | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| WO2008093064A1 (fr) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | Dérivés de la l-alanine en tant qu'antagonistes de l'α5β1 |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| US10214522B2 (en) | 2015-03-10 | 2019-02-26 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CN104817604B (zh) | 2015-03-16 | 2017-08-04 | 邦泰生物工程(深圳)有限公司 | 一种β‑烟酰胺单核苷酸的纯化方法 |
| CN108040467A (zh) * | 2015-04-30 | 2018-05-15 | 赛弗卢尔生命科学公司 | 四氢萘啶基丙酸衍生物及其用途 |
| WO2018009501A1 (fr) | 2016-07-05 | 2018-01-11 | The Rockefeller University | Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide |
| EP3509590A4 (fr) * | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | Composés d'acides aminés n-acyle et méthodes d'utilisation |
| JP7264810B2 (ja) * | 2016-11-08 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | アルファｖインテグリン阻害剤としてのシクロブタン－およびアゼチジン－含有の単環およびスピロ環式化合物 |
| EP3558303A4 (fr) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | Composés acides aminés et leurs procédés d'utilisation |
| US11046685B2 (en) * | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP3589627A4 (fr) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
| DK3761980T3 (da) | 2018-03-07 | 2024-01-29 | Pliant Therapeutics Inc | Aminosyreforbindelser og fremgangsmåder til anvendelse |
| CU24693B1 (es) | 2018-06-27 | 2024-02-07 | Pliant Therapeutics Inc | Compuestos de aminoácido con enlazadores no ramificados como inhibidores de la integrina |
| WO2020047207A1 (fr) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibiteurs de l'intégrine (alpha-v)(bêta -6) |
| PE20211640A1 (es) | 2018-08-29 | 2021-08-24 | Morphic Therapeutic Inc | INHIBICION DE LA INTEGRINA xvß6 |
| EP3843727A4 (fr) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | Inhibiteurs de l'intégrine (alpha-v)(bêta-6) |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| JP2022526818A (ja) | 2019-04-08 | 2022-05-26 | プライアント・セラピューティクス・インコーポレイテッド | アミノ酸化合物の剤形およびレジメン |
| CA3163339A1 (fr) | 2019-11-15 | 2021-05-20 | Pliant Therapeutics, Inc. | Compositions et methodes pour l'activation d'integrines |
| CA3173761A1 (fr) | 2020-05-07 | 2021-11-11 | Eric Lefebvre | Traitement de maladies respiratoires avec des composes acides amines |
| EP4247472A1 (fr) | 2020-11-19 | 2023-09-27 | Pliant Therapeutics, Inc. | Inhibiteur d'intégrine et ses utilisations |
| TW202308637A (zh) | 2021-04-30 | 2023-03-01 | 美商普萊恩醫療公司 | 整合素抑制劑之擴大劑量方案 |
| CA3173754A1 (fr) | 2021-09-03 | 2024-03-02 | Pliant Therapeutics, Inc. | Modulation therapeutique des integrines |
| TW202329973A (zh) | 2021-10-14 | 2023-08-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
-
2019
- 2019-06-27 CU CU2021000001A patent/CU24693B1/es unknown
- 2019-06-27 JP JP2020572976A patent/JP7425757B2/ja active Active
- 2019-06-27 EA EA202190134A patent/EA202190134A1/ru unknown
- 2019-06-27 AU AU2019295769A patent/AU2019295769B2/en active Active
- 2019-06-27 IL IL279717A patent/IL279717B2/en unknown
- 2019-06-27 MX MX2020014086A patent/MX2020014086A/es unknown
- 2019-06-27 WO PCT/US2019/039624 patent/WO2020006315A1/fr active Application Filing
- 2019-06-27 PE PE2020002165A patent/PE20210137A1/es unknown
- 2019-06-27 CR CR20210041A patent/CR20210041A/es unknown
- 2019-06-27 US US16/455,490 patent/US11396506B2/en active Active
- 2019-06-27 KR KR1020217002250A patent/KR20210043561A/ko active Search and Examination
- 2019-06-27 CA CA3104682A patent/CA3104682A1/fr active Pending
- 2019-06-27 EP EP19826330.3A patent/EP3813818A4/fr active Pending
- 2019-06-27 CN CN201980050125.6A patent/CN112689507A/zh active Pending
- 2019-06-27 BR BR112020026278-1A patent/BR112020026278A2/pt unknown
- 2019-06-27 IL IL308960A patent/IL308960A/en unknown
- 2019-06-27 SG SG11202013027RA patent/SG11202013027RA/en unknown
- 2019-06-27 JO JOP/2020/0330A patent/JOP20200330A1/ar unknown
-
2020
- 2020-12-23 DO DO2020000255A patent/DOP2020000255A/es unknown
- 2020-12-23 CL CL2020003382A patent/CL2020003382A1/es unknown
- 2020-12-23 PH PH12020552260A patent/PH12020552260A1/en unknown
-
2021
- 2021-01-26 EC ECSENADI20215655A patent/ECSP21005655A/es unknown
-
2022
- 2022-02-23 US US17/679,002 patent/US11858931B2/en active Active
-
2024
- 2024-01-19 JP JP2024006536A patent/JP2024055873A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279717A (en) | Amino acid compounds with non-branched linkers and methods of use | |
| IL277146A (en) | Amino acid compounds and methods of use | |
| IL281783A (en) | SIRPa type binding proteins and methods of using them | |
| IL276731A (en) | Antibodies against CD73 and methods of using them | |
| IL282026A (en) | Amino acid compounds and methods of use | |
| EP3509590A4 (fr) | Composés d'acides aminés n-acyle et méthodes d'utilisation | |
| IL261666A (en) | Related proteins and methods of using them | |
| IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| EP3558303A4 (fr) | Composés acides aminés et leurs procédés d'utilisation | |
| IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
| IL270214A (en) | Anti-sortilin antibodies and methods of using them | |
| IL279201A (en) | Multispecific binding proteins and methods of using them | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
| IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
| IL283884A (en) | Antibodies against il-36 and methods of using them | |
| IL280338A (en) | Anti-SIGLEC-5 antibodies and methods of using them | |
| IL279227A (en) | Anti-SIGLEC-7 antibodies and methods of using them | |
| EP4025585A4 (fr) | Peptides modifiés et procédés d'utilisation associés | |
| EP3849663C0 (fr) | Composés pyrimidinyl-hétéroaryloxy-naphtyle et procédés d'utilisation |